Immunome (NASDAQ:IMNM) Releases Earnings Results, Misses Expectations By $0.14 EPS

Immunome (NASDAQ:IMNM) announced its quarterly earnings data on Monday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14), FiscalAI reports.

Immunome Trading Up 2.2%

NASDAQ IMNM traded up $0.40 during trading hours on Wednesday, reaching $19.05. The company had a trading volume of 389,573 shares, compared to its average volume of 1,375,610. The stock has a 50-day moving average of $21.15 and a 200 day moving average of $22.33. Immunome has a 1-year low of $16.11 and a 1-year high of $30.06. The stock has a market capitalization of $2.16 billion, a P/E ratio of -7.21 and a beta of 2.68.

Insiders Place Their Bets

In other Immunome news, insider Jack Higgins sold 13,200 shares of Immunome stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider directly owned 65,050 shares in the company, valued at $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.21% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on IMNM shares. HC Wainwright reiterated a “buy” rating on shares of Immunome in a report on Tuesday, October 27th. Stifel Nicolaus cut their price target on shares of Immunome from $24.00 to $23.00 and set a “hold” rating for the company in a report on Tuesday. Alliance Global Partners started coverage on shares of Immunome in a research report on Monday, September 21st. They set a “buy” rating and a $32.00 price target on the stock. Wall Street Zen cut Immunome from a “sell” rating to a “strong sell” rating in a report on Sunday, October 4th. Finally, Truist Financial increased their price objective on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.85.

Key Immunome News

Here’s some of the latest news about IMNM:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and issued 2027 quarterly EPS estimates ranging from a loss of $0.72 to a loss of $0.60. Immunome analyst coverage
• Positive Sentiment: Piper Sandler lowered its price target from $33 to $30 but kept an “Overweight” rating; the revised target remains above the cited share price. Piper Sandler recommendations
• Negative Sentiment: Stifel Nicolaus cut its price target from $24 to $23 and maintained a “Hold” rating, signaling a more cautious outlook, although the target remains above the cited share price. Stifel Nicolaus recommendations

About Immunome

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.